X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1342) 1342
alpha-synuclein (1093) 1093
humans (915) 915
animals (875) 875
parkinson's disease (630) 630
neurosciences (603) 603
parkinsons-disease (532) 532
biochemistry & molecular biology (407) 407
mice (349) 349
alpha-synuclein - metabolism (324) 324
alzheimers-disease (318) 318
oxidative stress (298) 298
neurodegeneration (269) 269
neurodegenerative diseases (252) 252
male (250) 250
rats (246) 246
parkinson disease - metabolism (239) 239
proteins (229) 229
neurons (227) 227
α-synuclein (219) 219
dopamine (213) 213
neurology (199) 199
cell biology (192) 192
nervous system diseases (190) 190
disease models, animal (188) 188
nervous system (177) 177
alpha-synuclein - genetics (176) 176
pharmacology & pharmacy (171) 171
analysis (169) 169
neurons - metabolism (166) 166
substantia-nigra (165) 165
lewy bodies (163) 163
parkinson’s disease (157) 157
clinical neurology (156) 156
brain (152) 152
mutation (152) 152
parkinson disease - pathology (152) 152
alzheimer's disease (151) 151
parkinson disease - genetics (150) 150
apoptosis (146) 146
article (146) 146
in-vitro (142) 142
dopamine - metabolism (141) 141
parkinsons disease (139) 139
movement disorders (132) 132
parkinson disease - drug therapy (130) 130
female (129) 129
neurons - drug effects (126) 126
mice, inbred c57bl (124) 124
research (123) 123
mouse model (117) 117
cell line, tumor (115) 115
cells, cultured (115) 115
synuclein (113) 113
brain - metabolism (112) 112
alpha-synuclein - antagonists & inhibitors (109) 109
cell-death (107) 107
autophagy (105) 105
neurons - pathology (104) 104
dopaminergic-neurons (103) 103
cell line (102) 102
nerve tissue proteins - metabolism (101) 101
neuroprotection (101) 101
protein (101) 101
aggregation (100) 100
toxicity (98) 98
parkinson disease (97) 97
expression (95) 95
parkinson disease - physiopathology (94) 94
physiological aspects (94) 94
dose-response relationship, drug (93) 93
neuroprotective agents - pharmacology (93) 93
multidisciplinary sciences (90) 90
neurodegenerative diseases - metabolism (90) 90
neurotoxicity (88) 88
disease (87) 87
phosphorylation (87) 87
mice, transgenic (86) 86
pc12 cells (86) 86
gene expression (84) 84
pathology (84) 84
in-vivo (83) 83
pathogenesis (83) 83
biomedicine (81) 81
cell death (81) 81
protein binding (80) 80
cell survival - drug effects (79) 79
rodents (79) 79
health aspects (77) 77
research article (77) 77
substantia nigra - metabolism (76) 76
nerve tissue proteins - genetics (75) 75
apoptosis - drug effects (74) 74
degeneration (74) 74
huntingtons-disease (74) 74
synucleins (74) 74
inflammation (73) 73
inhibition (73) 73
mitochondria (73) 73
dopaminergic neurons - metabolism (71) 71
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


MOVEMENT DISORDERS, ISSN 0885-3185, 09/2018, Volume 33, Issue 9, pp. 1465 - 1471
Background: beta 2-adrenoreceptors have recently been identified as regulators of the alpha-synuclein gene, which is implicated in the pathogenesis of... 
beta 2-antagonists | Parkinson's disease | beta 2-agonists | beta-blockers | ALPHA-SYNUCLEIN | CALCIUM-CHANNEL BLOCKERS | DURATION | CLINICAL NEUROLOGY
Journal Article
The EMBO Journal, ISSN 0261-4189, 12/2009, Volume 28, Issue 23, pp. 3758 - 3770
Journal Article
Cell Metabolism, ISSN 1550-4131, 07/2014, Volume 20, Issue 1, pp. 145 - 157
Neurodegenerative diseases represent an increasing burden in our aging society, yet the underlying metabolic factors influencing onset and progression remain... 
LONGEVITY | MUTANTS | CAENORHABDITIS-ELEGANS | PROTEIN | PROTEOTOXICITY | DROSOPHILA LIFE-SPAN | DISEASE | ENDOCRINOLOGY & METABOLISM | ALPHA-SYNUCLEIN | GENE-EXPRESSION CHANGES | C.-ELEGANS | CELL BIOLOGY | Caenorhabditis elegans Proteins - metabolism | Male | Insulin Receptor Substrate Proteins - metabolism | Drosophila Proteins - metabolism | Dopaminergic Neurons - cytology | Glucose-6-Phosphate Isomerase - genetics | RNA Interference | Forkhead Transcription Factors - metabolism | Receptor, Insulin - genetics | Dopaminergic Neurons - metabolism | Aging | Parkinson Disease - metabolism | Insulin Receptor Substrate Proteins - genetics | Cytokines - genetics | Drosophila Proteins - antagonists & inhibitors | Disease Models, Animal | Parkinson Disease - pathology | Caenorhabditis elegans - metabolism | Cytokines - metabolism | Signal Transduction | Cells, Cultured | Transcription Factors - antagonists & inhibitors | Transcription Factors - genetics | Receptor, Insulin - antagonists & inhibitors | alpha-Synuclein - chemistry | Glucose-6-Phosphate Isomerase - metabolism | Transcription Factors - metabolism | Animals | Caenorhabditis elegans Proteins - antagonists & inhibitors | Glucose-6-Phosphate Isomerase - antagonists & inhibitors | Glucose - metabolism | Glycolysis | Receptor, Insulin - metabolism | Mice | Cytokines - antagonists & inhibitors | Drosophila - metabolism | Drosophila Proteins - genetics | Caenorhabditis elegans Proteins - genetics | alpha-Synuclein - metabolism | Insulin-Like Growth Factor I - metabolism | RNA, Small Interfering - metabolism | Glucose metabolism | Enzymes | Medical colleges | Analysis | Physiological aspects | Cystic fibrosis | Glucose | Dextrose | Neurophysiology | Insulin | Index Medicus
Journal Article
Brain Behavior and Immunity, ISSN 0889-1591, 02/2019, Volume 76, pp. 61 - 73
The activation of microglial cells is presumed to play a key role in the pathogenesis of Parkinson's disease (PD). The activity of microglia is regulated by... 
α-Synuclein | Histamine 4 receptor antagonist | Parkinson’s disease | Rotenone | Microglia | Parkinson's disease | NERVOUS-SYSTEM | ACTIVATION | HUMAN BRAIN | PSYCHIATRY | DOPAMINERGIC-NEURONS | H-4-RECEPTOR | IMMUNOLOGY | SUBSTANTIA-NIGRA | NEUROSCIENCES | DEGENERATION | DISEASE | H-4 RECEPTOR | alpha-Synuclein | Medicine, Experimental | Medical research | Histamine | RNA
Journal Article
Molecules, ISSN 1420-3049, 2018, Volume 23, Issue 8, p. 1837
A series of fourteen new asymmetrical 1,3-diketone derivatives have been synthesized and evaluated in the ABTS, FRAP and DPPH assays as a new chemotype with... 
Oxidative stress | Drug-like properties | Antioxidant | Neurodegeneration | Neuroprotectant | Β-diketones | antioxidant | LIPID-PEROXIDATION | ALZHEIMERS-DISEASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | neurodegeneration | drug-like properties | ALPHA-SYNUCLEIN | FREE-RADICAL METHOD | CHEMISTRY, MULTIDISCIPLINARY | NEURODEGENERATIVE DISEASES | beta-diketones | neuroprotectant | MITOCHONDRIAL DYSFUNCTION | THERAPEUTIC STRATEGIES | PRECURSOR PROTEIN | oxidative stress | PARKINSONS-DISEASE | Apoptosis - drug effects | Quinones - chemical synthesis | Humans | Neurons - cytology | Structure-Activity Relationship | Membrane Potential, Mitochondrial - drug effects | Iron Chelating Agents - chemical synthesis | Neuroprotective Agents - pharmacology | Biphenyl Compounds - antagonists & inhibitors | Ketones - chemical synthesis | Inhibitory Concentration 50 | Benzothiazoles - antagonists & inhibitors | Neurons - metabolism | Neurons - drug effects | Quinones - pharmacology | Ketones - pharmacology | Cell Survival - drug effects | Curcumin - pharmacology | Hydrogen Peroxide - pharmacology | Antioxidants - chemical synthesis | Antioxidants - pharmacology | Sulfonic Acids - antagonists & inhibitors | Neuroprotective Agents - chemical synthesis | Picrates - antagonists & inhibitors | Iron Chelating Agents - pharmacology | Cell Line, Tumor | Oxidative Stress - drug effects | Hydrogen Peroxide - antagonists & inhibitors | Neuroprotection | Hydrogen peroxide | Neurodegenerative diseases | Toxicity | Cytotoxicity | Pharmacology | Derivatives | Neuroprotective agents | Chemical compounds | Neurological diseases | Antioxidants | Diketones | Organic chemistry | Mitochondria | Fluorescence recovery after photobleaching | Chelation | Curcumin | Membrane potential | Index Medicus | β-diketones
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2016, Volume 11, Issue 10, pp. e0164465 - e0164465
We have been investigating the role that phosphatidylethanolamine (PE) and phosphatidylcholine (PC) content plays in modulating the solubility of the... 
PHOSPHATIDYLETHANOLAMINE | CAENORHABDITIS-ELEGANS | INHIBITION | MULTIDISCIPLINARY SCIENCES | ALPHA-SYNUCLEIN | ARACHIDONIC-ACID | SUBSTANTIA-NIGRA | BRAIN | PERMEABILITY TRANSITION | CELL-DEATH | CYCLOSPORINE | Carboxy-Lyases - antagonists & inhibitors | Cyclosporine - pharmacology | Transferases (Other Substituted Phosphate Groups) - genetics | Caenorhabditis elegans Proteins - metabolism | Transferases (Other Substituted Phosphate Groups) - antagonists & inhibitors | Mitochondrial Proteins - genetics | Phosphatidylcholines - metabolism | Carboxy-Lyases - genetics | Sulfaphenazole - pharmacology | Saccharomyces cerevisiae - metabolism | Transferases (Other Substituted Phosphate Groups) - metabolism | Meclofenoxate - pharmacology | Mitochondrial Proteins - metabolism | Protective Agents - pharmacology | Dopaminergic Neurons - metabolism | Dopaminergic Neurons - drug effects | Carboxy-Lyases - metabolism | Membrane Proteins - metabolism | Parkinson Disease - metabolism | Disease Models, Animal | Parkinson Disease - pathology | Endoplasmic Reticulum Stress - drug effects | Membrane Proteins - genetics | Mitochondrial Proteins - antagonists & inhibitors | Solubility | Mitochondria - metabolism | alpha-Synuclein - chemistry | Caenorhabditis elegans | Animals | Caenorhabditis elegans Proteins - antagonists & inhibitors | Membrane Proteins - antagonists & inhibitors | Phosphatidylethanolamines - metabolism | Caenorhabditis elegans Proteins - genetics | alpha-Synuclein - metabolism | Enzymes | Membrane lipids | Neurons | Models | Phospholipids | Cardiolipin | Drug approval | Index Medicus
Journal Article
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 05/2016, Volume 36, Issue 18, pp. 5144 - 5159
Journal Article
Journal Article
Science, ISSN 0036-8075, 09/2017, Volume 357, Issue 6354, pp. 891 - 898
Journal Article
Journal Article
Journal of Neurochemistry, ISSN 0022-3042, 12/2011, Volume 119, Issue 5, pp. 1119 - 1136
Loss of dopaminergic neurons and a-synuclein accumulation are the two major pathological hallmarks of Parkinsons disease. Currently, the mechanisms governing... 
Parkinson's disease | 27-hydroxycholesterol | liver X receptor | estrogen receptors | α-synuclein | tyrosine hydroxylase | CAMP RESPONSE ELEMENT | OXIDATIVE STRESS | BIOCHEMISTRY & MOLECULAR BIOLOGY | NEUROSCIENCES | MESSENGER-RNA LEVELS | LXR-ALPHA | NUCLEAR RECEPTOR | BETA-DEFICIENT MICE | GENE-EXPRESSION | INDUCED DOPAMINE DEPLETION | NEURONAL CELLS | RAT-BRAIN | a-synuclein | Humans | Neuroblastoma - enzymology | Estrogen Receptor alpha - agonists | Estrogen Receptor beta - agonists | alpha-Synuclein - biosynthesis | Estrogen Receptor beta - biosynthesis | Liver X Receptors | Up-Regulation - physiology | Parkinson Disease - metabolism | alpha-Synuclein - genetics | Estrogen Receptor beta - antagonists & inhibitors | Neuroblastoma - pathology | Orphan Nuclear Receptors - agonists | Tyrosine 3-Monooxygenase - antagonists & inhibitors | Estrogen Receptor alpha - antagonists & inhibitors | Signal Transduction - genetics | Down-Regulation - drug effects | Hydroxycholesterols - pharmacology | Orphan Nuclear Receptors - biosynthesis | Disease Progression | Down-Regulation - physiology | Up-Regulation - drug effects | Tyrosine 3-Monooxygenase - biosynthesis | Tyrosine 3-Monooxygenase - genetics | Orphan Nuclear Receptors - antagonists & inhibitors | Parkinson Disease - prevention & control | Parkinson Disease - enzymology | Cell Line, Tumor | Signal Transduction - physiology | Estrogen Receptor alpha - biosynthesis | Neuroblastoma - metabolism | Index Medicus
Journal Article